Discussion in 'BioMedical ME/CFS Research' started by Andy, Aug 30, 2019.
Sci hub, not available
Interesting. That's two systematic reviews of cytokines in ME/CFS published this week.
The other one concluded the results across studies were too inconstent to be useful as biomarkers.
I'm a bit wary of this paper given where the authors are based
Rebecca Strawbridge, Maria-Laura Sartor,Fraser Scott, Anthony J.Cleare
Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
No, yet ironic that non friends are talking about subgroups, which is where imho we all need to be heading.
Call me cynical, but the devil is in the detail and how they or their colleagues try to use it, perhaps to justify a PACE II.
Interesting that (from Trish's link) Marshall-Gradisnik et al arrive at the same kind of conclusion about inconsistency. I think its a valid observation.
They (Aussies) are talking about case definitions and homogenous CFS/ME/SEID populations which I believe translates as criteria and cohorts. Again IMHO this is subtyping and is where we have to be heading, all the more so after EDS/CCI became such a hot topic. And while mitochondria are a bone of contention inflammatory markers would surely be another approach worth persuing in parallel, particularly if we are envisaging multiple subtypes, the more methods for discerning differences the better.
Didn't see this previously posted:
"Neurosci Biobehav Rev. 2019 Dec;107:69-83. doi: 10.1016/j.neubiorev.2019.08.011. Epub 2019 Aug 26.
Inflammatory proteins are altered in chronic fatigue syndrome-A systematic review and meta-analysis.
Strawbridge R1, Sartor ML2, Scott F2, Cleare AJ2.
Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. Electronic address: Becci.email@example.com.
Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Immune dysfunction has been posited as a key element in the aetiology of chronic fatigue syndrome (CFS) since the illness was first conceived. However, systematic reviews have yet to quantitatively synthesise inflammatory biomarkers across the literature. We undertook a systematic review and meta-analysis to quantify available data on circulating inflammatory proteins, examining studies recruiting patients with a CFS diagnosis and a non-affected control group. Results were meta-analysed from 42 studies.
Patients with CFS had significantly elevated tumour necrosis factor (ES = 0.274, p < 0.001), interleukin-2 (ES = 0.203, p = 0.006), interleukin-4 (ES = 0.373, p = 0.004), transforming growth factor-β (ES = 0.967, p < 0.001) and c-reactive protein (ES = 0.622, p = 0.019). 12 proteins did not differ between groups.
These data provide some support for an inflammatory component in CFS, although inconsistency of results indicates that inflammation is unlikely to be a primary feature in all those suffering from this disorder. It is hoped that further work will elucidate whether there are subgroups of patients with clinically-relevant inflammatory dysfunction, and whether inflammatory cytokines may provide a prognostic biomarker or moderate treatment effects."
Scihub link, https://sci-hub.se/10.1016/j.neubiorev.2019.08.011
so I make that the majority of the studies used in the review, and therefore the results of this review, should be considered iffy on grounds of the selection criteria used.
King's college (and Anthony Cleare who is presumably AJ Cleare) are BPSers. I think they do this work to show they are looking at biology, but, sigh, there is nothing much there despite the protests of patients.
It may not apply here, not read the paper, but the problem with studies of immune dysfunction has always been that while it goes wrong in most patients, in some it goes up in others it goes down and there is no consistency. It is like the control of the immune system is wrong rather than any individual bit.
Then we have the problem that things are worse for us in PEM - that is when I get inflammatory symptoms - but then it goes back to normal.
Separate names with a comma.